The future of clinical trials involves real-world data collected from wearable sensors and connected technologies. Pharmaceutical companies are investing heavily in digital innovation; however, the adoption of digital biomarkers remains slow. These data types can be incredibly complex and sensitive, prone to artifact, and challenging to interpret, leaving research teams overwhelmed with no clear path to success.
In this eBook, 4 Key Principles of Digital Biomarker Development, Dudley Tabakin, VivoSense CEO, and Kate Lyden, PhD. discuss their approach to realizing the potential of digital solutions in clinical trials:
You'll learn how and why these principles are most impactful when biomarker development is conducted in early-stage clinical trials or early pilot studies.